CTI BioPharma, Baxter Say Pacritinib Phase 3 Study Data To Be Presented At ASCO

(RTTNews) - CTI BioPharma Corp. (CTIC) and Baxter International Inc. (BAX) said data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis would be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology or ASCO 2015 Meeting.

These data have also been selected as part of this year's official ASCO press briefing - titled "Targeted Therapy" - to be held on Saturday, May 30.

Myelofibrosis is a rare, but serious and life-threatening chronic bone marrow disorder caused by the accumulation of malignant bone marrow cells that triggers an inflammatory response and scars the bone marrow.

The replacement of bone marrow with scar tissue limits its ability to produce red blood cells, prompting the spleen and liver to take over this function. Pacritinib is a next generation JAK2/FLT3 inhibitor under investigation for the treatment of patients with myelofibrosis.